Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ImageneBio Inc (IMA)
USD6.27
+0.25 (+4.15%)
US NASDAQ Healthcare Biotechnology
Address
12526 High Bluff Drive, Suite 345, San Diego, CA 92130 92130
San Diego, CA, US
San Diego, CA, US
CEO
Kristin Yarema
Website
inmagenebio.com
IPO
1998-02-27
CIK 1835579 ISIN US45175G2075
Also trades on
NASDAQ Global Market · IKNA (USD)
NASDAQ Global Market · IMA (USD)
Description
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
News Sentiment (7d)
Based on only 1 article — low confidence
- ImageneBio Appoints Matt Robbins as General Counsel GlobeNewsWire
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD6.27
+0.25 (+4.15%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
351.7K
Beta
0.73
Float Shares
7.00M
Free Float %
62.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.96% | -5.45% | +16.73% | -16.50% | -33.10% | -17.10% | -58.19% | -93.19% | -97.56% | -98.51% | -98.51% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
6.27
Low
1.33
-78.8%
Consensus
1.33
-78.8%
Median
1.33
-78.8%
High
1.33
-78.8%
DCF (Unlevered)
4.99
-20.4%
DCF (Levered)
4.98
-20.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
67% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 2 |
1.67
-73.4%
|
Quality scores
Altman Z-Score
0.09
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-77.1%
-
EPS growth Biotechnology: +29.7%-954.9% Q1'26: -427.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-8,282.0%
-
EBIT margin Biotechnology: +0.0%-6,056.4%
-
ROIC Biotechnology: -16.1%-71.9% Q1'26: -338.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-89.9% ★ Q1'26: -76.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.21× Q1'26: -0.17× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
30.99M
est: 15.56M (+99.1%)
|
15.62M
est: 16.18M (-3.5%)
|
9.16M
est: 11.87M (-22.8%)
|
3.50M
est: 3.50M (+0.0%)
|
800.0K
est: 266.7K (+200.0%)
|
340.2K
340.2K – 340.2K
+27.6% YoY
|
144.7K
144.7K – 144.7K
-57.5% YoY
|
61.5K
61.5K – 61.5K
-57.5% YoY
|
26.2K
26.2K – 26.2K
-57.5% YoY
|
20.50M
20.50M – 20.50M
+78,219.0% YoY
|
| EBITDA |
-33.59M
est: -15.56M (-115.9%)
|
-70.15M
est: -16.18M (-333.5%)
|
-74.40M
est: -11.87M (-526.7%)
|
-35.47M
est: -3.50M (-913.5%)
|
-47.42M
est: -266.7K (-17,681.7%)
|
-340.2K
-340.2K – -340.2K
-27.6% YoY
|
-144.7K
-144.7K – -144.7K
+57.5% YoY
|
-61.5K
-61.5K – -61.5K
+57.5% YoY
|
-26.2K
-26.2K – -26.2K
+57.5% YoY
|
-20.50M
-20.50M – -20.50M
-78,219.0% YoY
|
| EBIT |
-34.14M
est: -15.56M (-119.4%)
|
-70.90M
est: -16.18M (-338.1%)
|
-75.42M
est: -11.87M (-535.3%)
|
-37.00M
est: -3.50M (-957.1%)
|
-48.45M
est: -266.7K (-18,069.1%)
|
-340.2K
-340.2K – -340.2K
-27.6% YoY
|
-144.7K
-144.7K – -144.7K
+57.5% YoY
|
-61.5K
-61.5K – -61.5K
+57.5% YoY
|
-26.2K
-26.2K – -26.2K
+57.5% YoY
|
-20.50M
-20.50M – -20.50M
-78,219.0% YoY
|
| Net Income |
-34.12M
est: -1.57B (+97.8%)
|
-68.77M
est: -935.84M (+92.7%)
|
-68.17M
est: -940.12M (+92.7%)
|
-36.57M
est: -64.72M (+43.5%)
|
-45.35M
est: -27.12M (-67.2%)
|
-21.46M
-34.68M – -8.25M
+20.8% YoY
|
-13.79M
-24.02M – -3.55M
+35.8% YoY
|
-19.26M
-19.45M – -19.06M
-39.6% YoY
|
-17.41M
-17.41M – -17.41M
+9.6% YoY
|
-18.87M
-18.87M – -18.87M
-8.4% YoY
|
| SGA |
18.02M
est: 25.16M (-28.4%)
|
22.20M
est: 26.17M (-15.2%)
|
24.93M
est: 19.20M (+29.8%)
|
8.39M
est: 23.12M (-63.7%)
|
20.73M
est: 1.76M (+1,076.6%)
|
2.25M
2.25M – 2.25M
+27.6% YoY
|
955.9K
955.9K – 955.9K
-57.5% YoY
|
406.5K
406.5K – 406.5K
-57.5% YoY
|
172.9K
172.9K – 172.9K
-57.5% YoY
|
135.42M
135.42M – 135.42M
+78,219.2% YoY
|
| EPS |
-0.95
est: -32.48 (+97.1%)
|
-1.90
est: -19.39 (+90.2%)
|
-1.63
est: -19.48 (+91.6%)
|
-1.02
est: -13.29 (+92.3%)
|
-10.76
est: -5.57 (-93.3%)
|
-4.10
-7.12 – -1.69
+26.3% YoY
|
-3.07
-4.93 – -0.73
+25.2% YoY
|
-3.95
-3.99 – -3.91
-28.8% YoY
|
-3.57
-3.57 – -3.57
+9.6% YoY
|
-3.88
-3.88 – -3.88
-8.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-52.08M
OE per share TTM
-3.84
Owner's Yield
-0.09%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
38.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
40
Total invested
32.92M
Insider transactions (90d)
0
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Blue Owl Capital Holdings LP | 4.09M | 8.48% | 4.09M | — | 4.09M | — | PN | — | 2024-11-14 | ↗ |
| 2 | Abigail P. Johnson | 3.78M | 12.54% | — | — | 3.78M | — | IN | United States of America | 2021-04-12 | ↗ |
| 3 | FMR LLC | 3.78M | 12.54% | 254.8K | — | 3.78M | — | HC | Delaware | 2021-04-12 | ↗ |
| 4 | Gilead Sciences, Inc. | 2.93M | 6.70% | 2.93M | — | 2.93M | — | CO | Delaware | 2023-10-19 | ↗ |
| 5 | ATLAS VENTURE ASSOCIATES X, L.P. | 2.90M | 8.10% | — | 2.90M | — | 10.00 | PN | Delaware | 2022-02-11 | ↗ |
| 6 | ATLAS VENTURE FUND X, L.P. | 2.90M | 8.10% | — | 2.90M | — | 10.00 | PN | Delaware | 2022-02-11 | ↗ |
| 7 | OrbiMed Advisors LLC | 2.34M | 5.50% | — | 2.34M | — | 10.00 | IA | Delaware | 2023-09-14 | ↗ |
| 8 | OrbiMed Capital GP VI LLC | 2.25M | 5.30% | — | 2.25M | — | 10.00 | OO | Delaware | 2023-09-14 | ↗ |
| 9 | Anne-Mari Paster | 2.25M | 6.30% | — | 2.25M | — | 2.25M | IN | — | 2022-02-14 | ↗ |
| 10 | Claudio Nessi | 2.25M | 6.30% | — | 2.25M | — | 2.25M | IN | — | 2022-02-14 | ↗ |
| 11 | Omega Fund VI GP Manager, Ltd. | 2.25M | 6.30% | — | 2.25M | — | 2.25M | OO | — | 2022-02-14 | ↗ |
| 12 | Omega Fund VI GP, L.P. | 2.25M | 6.30% | — | 2.25M | — | 2.25M | PN | — | 2022-02-14 | ↗ |
| 13 | Omega Fund VI, L.P. | 2.25M | 6.30% | — | 2.25M | — | 2.25M | PN | — | 2022-02-14 | ↗ |
| 14 | Otello Stampacchia | 2.25M | 6.30% | — | 2.25M | — | 2.25M | IN | — | 2022-02-14 | ↗ |
| 15 | BRISTOL-MYERS SQUIBB COMPANY 22-0790350 | 2.13M | 5.90% | — | 2.13M | — | 2.13M | CO | Delaware, U.S.A. | 2021-04-05 | ↗ |
| 16 | CELGENE CORPORATION 22-2711928 | 2.13M | 5.90% | — | 2.13M | — | 2.13M | CO | Delaware, U.S.A. | 2021-04-05 | ↗ |
| 17 | BVF Inc. | 1.60M | 5.10% | — | — | — | 1.60M | CO | Delaware | 2021-04-05 | ↗ |
| 18 | BVF Partners L.P. | 1.60M | 5.10% | — | — | — | 1.60M | IA, PN | Delaware | 2021-04-05 | ↗ |
| 19 | Mark N. Lampert | 1.60M | 5.10% | — | — | — | 1.60M | IN | Delaware | 2021-04-05 | ↗ |
| 20 | BVF GP HOLDINGS LLC | 1.49M | 4.80% | — | — | — | 1.49M | OO | Delaware | 2021-04-05 | ↗ |
| 21 | ATLAS VENTURE ASSOCIATES XI, L.P. | 1.24M | 3.50% | — | 1.24M | — | 10.00 | PN | Delaware | 2022-02-11 | ↗ |
| 22 | ATLAS VENTURE FUND XI, L.P. | 1.24M | 3.50% | — | 1.24M | — | 10.00 | PN | Delaware | 2022-02-11 | ↗ |
| 23 | LLC | 1.24M | 3.50% | — | 1.24M | — | 10.00 | OO | Delaware | 2022-02-11 | ↗ |
| 24 | OrbiMed Capital LLC | 997.1K | 2.30% | 997.1K | — | 997.1K | 10.00 | IA | Delaware | 2023-09-14 | ↗ |
| 25 | I, L.P. | 874.6K | 2.40% | — | 874.6K | — | 10.00 | PN | Delaware | 2022-02-11 | ↗ |
| 26 | BVF I GP LLC | 853.1K | 2.70% | — | — | — | 853.1K | OO | Delaware | 2021-04-05 | ↗ |
| 27 | Biotechnology Value Fund, L.P. | 853.1K | 2.70% | — | — | — | 853.1K | PN | Delaware | 2021-04-05 | ↗ |
| 28 | BVF II GP LLC | 633.7K | 2.00% | — | — | — | 633.7K | OO | Delaware | 2021-04-05 | ↗ |
| 29 | Biotechnology Value Fund II, L.P. | 633.7K | 2.00% | — | — | — | 633.7K | PN | Delaware | 2021-04-05 | ↗ |
| 30 | BVF Partners OS Ltd. | 102.7K | 1.00% | — | — | — | 102.7K | CO | Delaware | 2021-04-05 | ↗ |
| 31 | Biotechnology Value Trading Fund OS LP | 102.7K | 1.00% | — | — | — | 102.7K | PN | Delaware | 2021-04-05 | ↗ |
| 32 | OrbiMed Genesis GP LLC | 91.0K | 0.20% | — | 91.0K | — | 10.00 | OO | Delaware | 2023-09-14 | ↗ |
| 33 | 2. | 10.00 | 6.60% | — | 2.05M | — | — | HC, PN | Delaware | 2021-04-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
40
+8 vs prev Q
New positions
14
Closed positions
6
Increased
26
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 26.5K +26.5K (+100.0%) | 182.85M +182.9M (+100.0%) | 0.31% +0.311 pp | 0.16% +0.156 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 2 | BLUE OWL CAPITAL HOLDINGS LP | 823.8K +282.9K (+52.3%) | 5.68M +1.3M (+28.9%) | 9.66% +3.317 pp | 0.43% -0.943 pp | USD7.72 -10.6% | 2 qtrs — |
| 3 | BVF INC/IL | 802.1K +— (+0.0%) | 5.53M -1.0M (-15.3%) | 9.41% +0.000 pp | 0.19% -0.079 pp | USD8.15 -15.3% | 2 qtrs — |
| 4 | CABLE CAR CAPITAL LLC | 643.9K +643.9K (+100.0%) | 4.44M +4.4M (+100.0%) | 7.55% +7.552 pp | 0.15% +0.148 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 5 | OMEGA FUND MANAGEMENT, LLC | 455.4K +— (+0.0%) | 3.14M -569.2K (-15.3%) | 5.34% +0.000 pp | 1.10% -0.572 pp | USD8.15 -15.3% | 2 qtrs — |
| 6 | ORBIMED ADVISORS LLC | 378.6K +— (+0.0%) | 2.61M -473.2K (-15.3%) | 4.44% +0.000 pp | 0.05% -0.019 pp | USD8.15 -15.3% | 2 qtrs — |
| 7 | RTW INVESTMENTS, LP | 334.4K +— (+0.0%) | 2.31M -418.1K (-15.3%) | 3.92% +0.000 pp | 0.02% -0.011 pp | USD8.15 -15.3% | 2 qtrs — |
| 8 | VANGUARD GROUP INC | 238.0K +4.6K (+2.0%) | 1.64M -259.7K (-13.7%) | 2.79% +0.054 pp | 0.00% +0.000 pp | USD8.13 -15.1% | 2 qtrs — |
| 9 | BML CAPITAL MANAGEMENT, LLC | 177.0K -5.5K (-3.0%) | 1.22M -266.0K (-17.9%) | 2.08% -0.064 pp | 1.06% -0.306 pp | USD8.15 -15.3% | 2 qtrs — |
| 10 | BLACKROCK, INC. | 131.6K +79.5K (+152.5%) | 908.0K +483.2K (+113.8%) | 1.54% +0.932 pp | 0.00% +0.000 pp | USD7.40 -6.8% | 2 qtrs — |
| 11 | MONASHEE INVESTMENT MANAGEMENT LLC | 91.6K +91.6K (+100.0%) | 632.2K +632.2K (+100.0%) | 1.07% +1.075 pp | 0.36% +0.356 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 12 | CITADEL ADVISORS LLC | 86.5K -35.8K (-29.3%) | 596.7K -399.6K (-40.1%) | 1.01% -0.420 pp | 0.00% 0.000 pp | USD8.15 -15.3% | 2 qtrs — |
| 13 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 66.7K +— (+0.0%) | 460.0K -83.3K (-15.3%) | 0.78% +0.000 pp | 0.00% 0.000 pp | USD8.15 -15.3% | 2 qtrs — |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 66.1K +28.7K (+76.8%) | 456.1K +151.4K (+49.7%) | 0.78% +0.337 pp | 0.00% +0.000 pp | USD7.61 -9.3% | 2 qtrs — |
| 15 | GEODE CAPITAL MANAGEMENT, LLC | 54.1K +6.5K (+13.5%) | 373.6K -15.1K (-3.9%) | 0.64% +0.076 pp | 0.00% +0.000 pp | USD8.00 -13.8% | 2 qtrs — |
| 16 | NEA MANAGEMENT COMPANY, LLC | 50.0K +— (+0.0%) | 345.0K -62.5K (-15.3%) | 0.59% +0.000 pp | 0.02% -0.005 pp | USD8.15 -15.3% | 2 qtrs — |
| 17 | SQUAREPOINT OPS LLC | 48.2K +24.1K (+99.6%) | 332.8K +135.8K (+69.0%) | 0.57% +0.282 pp | 0.00% +0.000 pp | USD7.53 -8.4% | 2 qtrs — |
| 18 | DRW SECURITIES, LLC | 43.8K +43.8K (+100.0%) | 302.0K +302.0K (+100.0%) | 0.51% +0.513 pp | 0.01% +0.008 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 19 | HSBC HOLDINGS PLC | 34.2K +34.2K (+100.0%) | 233.1K +233.1K (+100.0%) | 0.40% +0.401 pp | 0.00% +0.000 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 20 | SOFINNOVA INVESTMENTS, INC. | 31.9K +— (+0.0%) | 220.0K -39.9K (-15.3%) | 0.37% +0.000 pp | 0.01% -0.005 pp | USD8.15 -15.3% | 2 qtrs — |
| 21 | SHAY CAPITAL LLC | 23.2K +23.2K (+100.0%) | 160.2K +160.2K (+100.0%) | 0.27% +0.272 pp | 0.02% +0.017 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 22 | ALDEBARAN CAPITAL, LLC | 19.1K -492.0 (-2.5%) | 131.6K -27.8K (-17.5%) | 0.22% -0.006 pp | 0.12% -0.029 pp | USD8.15 -15.3% | 2 qtrs — |
| 23 | JACOBS LEVY EQUITY MANAGEMENT, INC | 18.7K +1.0K (+5.8%) | 129.2K -15.1K (-10.5%) | 0.22% +0.012 pp | 0.00% 0.000 pp | USD8.08 -14.6% | 2 qtrs — |
| 24 | RANGELEY CAPITAL, LLC | 18.2K +3.2K (+21.6%) | 125.9K +3.6K (+3.0%) | 0.21% +0.038 pp | 0.10% -0.001 pp | USD7.93 -13.0% | 2 qtrs — |
| 25 | JANE STREET GROUP, LLC | 14.9K +14.9K (+100.0%) | 102.8K +102.8K (+100.0%) | 0.17% +0.175 pp | 0.00% +0.000 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 26 | PRELUDE CAPITAL MANAGEMENT, LLC | 13.5K +13.5K (+100.0%) | 93.1K +93.1K (+100.0%) | 0.16% +0.158 pp | 0.01% +0.007 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 27 | — | 13.2K +13.2K (+100.0%) | 91.1K +91.1K (+100.0%) | 0.15% +0.155 pp | 0.11% +0.113 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 28 | XTX TOPCO LTD | 12.2K +12.2K (+100.0%) | 84.0K +84.0K (+100.0%) | 0.14% +0.143 pp | 0.00% +0.002 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 29 | MILLENNIUM MANAGEMENT LLC | 11.5K +11.5K (+100.0%) | 79.0K +79.0K (+100.0%) | 0.13% +0.134 pp | 0.00% +0.000 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 30 | GOLDMAN SACHS GROUP INC | 11.0K +11.0K (+100.0%) | 75.6K +75.6K (+100.0%) | 0.13% +0.128 pp | 0.00% +0.000 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 31 | BARCLAYS PLC | 10.8K +6.8K (+170.8%) | 74.5K +42.0K (+129.3%) | 0.13% +0.080 pp | 0.00% +0.000 pp | USD7.36 -6.3% | 2 qtrs — |
| 32 | MORGAN STANLEY | 10.8K +9.5K (+737.6%) | 74.3K +63.8K (+609.1%) | 0.13% +0.111 pp | 0.00% +0.000 pp | USD7.05 -2.1% | 2 qtrs — |
| 33 | UBS GROUP AG | 5.0K +191.0 (+4.0%) | 34.2K -4.6K (-11.9%) | 0.06% +0.002 pp | 0.00% +0.000 pp | USD8.10 -14.8% | 2 qtrs — |
| 34 | BANK OF AMERICA CORP /DE/ | 2.6K +2.6K (+9,888.5%) | 17.9K +17.7K (+8,352.4%) | 0.03% +0.030 pp | 0.00% +0.000 pp | USD6.91 -0.1% | 2 qtrs — |
| 35 | ROYAL BANK OF CANADA | 1.0K +1.0K (+100.0%) | 7.0K +7.0K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 36 | NEWEDGE ADVISORS, LLC | 491.00 -12.5K (-96.2%) | 3.4K -102.2K (-96.8%) | 0.01% -0.146 pp | 0.00% -0.001 pp | USD8.15 -15.3% | 2 qtrs — |
| 37 | FORTITUDE FAMILY OFFICE, LLC | 400.00 +400.0 (+100.0%) | 2.8K +2.8K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.001 pp | USD6.90 +0.0% | 1 qtrs NEW |
| 38 | JPMORGAN CHASE & CO | 70.00 +— (+0.0%) | 483.00 -88.0 (-15.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.14 -15.2% | 2 qtrs — |
| 39 | WELLS FARGO & COMPANY/MN | 41.00 +— (+0.0%) | 283.00 -51.0 (-15.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.15 -15.3% | 2 qtrs — |
| 40 | BNP PARIBAS ARBITRAGE, SNC | 24.00 +— (+0.0%) | 166.00 -30.0 (-15.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.13 -15.1% | 2 qtrs — |
| 41 | DEEP TRACK CAPITAL, LP | — -878.5K (-100.0%) | — -7.2M (-100.0%) | 0.00% -10.303 pp | 0.00% -0.200 pp | USD— | 2 qtrs SOLD |
| 42 | ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC | — -377.8K (-100.0%) | — -3.1M (-100.0%) | 0.00% -4.431 pp | 0.00% -0.409 pp | USD— | 2 qtrs SOLD |
| 43 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | — -12.8K (-100.0%) | — -104.1K (-100.0%) | 0.00% -0.150 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 44 | FMR LLC | — -67.0 (-100.0%) | — -546.0 (-100.0%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 45 | TOWER RESEARCH CAPITAL LLC (TRC) | — -877.0 (-100.0%) | — -7.1K (-100.0%) | 0.00% -0.010 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 46 | FEDERATED HERMES, INC. | — -204.0 (-100.0%) | — -1.7K (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 157.8K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 292.3K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 3.2K | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 8.8K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 648.68 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 1.50M | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 3.3K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.8K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 723.49 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 79.74 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
1.44M
Shares disposed
—
Cash buys
4.00
Cash sales
—
Net activity
+1,442,584
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Su Wei-guo | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-04-14 | ORBIMED ADVISORS LLC | Director | P-Purchase | A | Pre-Funded Warrants (right to buy) | 384,689 | 0.00 | 384.69 | 384,689 | I | ↗ |
| 2026-04-14 | Bonita David P | Director | P-Purchase | A | Pre-Funded Warrants (right to buy) | 384,689 | 0.00 | 384.69 | 384,689 | I | ↗ |
| 2026-03-20 | Lally Robert B | Officer | — | — | Common Stock | 0 | 0.00 | — | 58,778 | D | ↗ |
| 2026-03-16 | Yarema Kristin | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 128,100 | 6.20 | 794.2K | 128,100 | D | ↗ |
| 2026-02-16 | Porter-Brown Benjamin | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-30 | Butler Erin | Officer | A-Award | A | Common Stock | 22,500 | 0.00 | — | 25,551 | D | ↗ |
| 2025-12-24 | SLATTERY JOSEPH P | Director | P-Purchase | A | Common Stock | 16,000 | 5.99 | 95.8K | 16,000 | D | ↗ |
| 2025-12-18 | Wang Stephen Hui | Director | A-Award | A | Employee Stock Option (Right to Buy) | 31,200 | 6.19 | 193.1K | 31,200 | D | ↗ |
| 2025-12-18 | Wang Jonathan Jian | Director | A-Award | A | Employee Stock Option (Right to Buy) | 31,200 | 6.19 | 193.1K | 31,200 | D | ↗ |
| 2025-12-18 | SLATTERY JOSEPH P | Director | A-Award | A | Employee Stock Option (Right to Buy) | 31,200 | 6.19 | 193.1K | 31,200 | D | ↗ |
| 2025-11-01 | SLATTERY JOSEPH P | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-28 | Yarema Kristin | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 460,515 | 16.37 | 7.54M | 460,515 | D | ↗ |
| 2025-07-28 | Marango Jotin | Officer | A-Award | A | Common Stock | 15,776 | 0.00 | — | 15,776 | D | ↗ |
| 2025-07-25 | Yarema Kristin | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-25 | Wang Stephen Hui | Director | A-Award | A | Common Stock | 188,042 | 0.00 | — | 188,042 | I | ↗ |
| 2025-07-25 | Wang Jonathan Jian | Director | A-Award | A | Common Stock | 143,832 | 0.00 | — | 143,832 | D | ↗ |
| 2025-07-25 | Stampacchia Otello | Director | M-Exempt | D | Stock Option (right to buy) | 17,520 | 1.75 | 30.7K | 0 | D | ↗ |
| 2025-07-25 | ORBIMED ADVISORS LLC | Director | A-Award | A | Common Stock | 83,611 | 2.49 | 208.2K | 287,885 | I | ↗ |
| 2025-07-25 | Marango Jotin | Officer | D-Return | D | Stock Option (Right to Buy) | 397,199 | 0.00 | — | 0 | D | ↗ |
| 2025-07-25 | Lu Yufang | Officer | A-Award | A | Employee Stock Option (right to buy) | 27,459 | 4.59 | 126.0K | 27,459 | D | ↗ |
| 2025-07-25 | Butler Erin | Officer | A-Award | A | Common Stock | 3,051 | 0.00 | — | 3,051 | D | ↗ |
| 2025-07-25 | Bonita David P | Director | P-Purchase | A | Common Stock | 83,611 | 29.90 | 2.50M | 287,885 | I | ↗ |
| 2024-06-07 | Wooster Richard | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 1.75 | 30.7K | 17,520 | — | ↗ |
| 2024-06-07 | Stampacchia Otello | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 1.75 | 30.7K | 17,520 | — | ↗ |
| 2024-06-07 | Koehler Maria | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 1.75 | 30.7K | 17,520 | — | ↗ |
| 2024-06-07 | Hughes Owen | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 1.75 | 30.7K | 17,520 | — | ↗ |
| 2024-06-07 | FORMELA JEAN FRANCOIS | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 1.75 | 30.7K | 17,520 | — | ↗ |
| 2024-06-07 | Dukes Iain D. | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 1.75 | 30.7K | 17,520 | — | ↗ |
| 2024-06-07 | Bonita David P | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 1.75 | 30.7K | 17,520 | — | ↗ |
| 2024-03-01 | Germa Caroline | Officer | A-Award | A | Stock Option (Right to Buy) | 579,100 | 1.47 | 851.3K | 579,100 | — | ↗ |
| 2024-02-29 | Germa Caroline | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-01 | Marango Jotin | Officer | A-Award | A | Stock Option (Right to Buy) | 181,000 | 1.36 | 246.2K | 181,000 | — | ↗ |
| 2024-02-01 | Manfredi Mark | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 320,000 | 1.36 | 435.2K | 320,000 | — | ↗ |
| 2024-02-01 | Ecsedy Jeffrey | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 1.36 | 136.0K | 100,000 | — | ↗ |
| 2023-08-04 | ORBIMED ADVISORS LLC | Director | A-Award | A | Common Stock | 153,121 | 0.00 | — | 2,251,218 | — | ↗ |
| 2023-08-04 | Bonita David P | Director | A-Award | A | Non-Voting Common Stock | 153,121 | 0.00 | — | 5,582,144 | — | ↗ |
| 2023-06-09 | Wooster Richard | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 6.51 | 114.1K | 17,520 | — | ↗ |
| 2023-06-09 | Stampacchia Otello | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 6.51 | 114.1K | 17,520 | — | ↗ |
| 2023-06-09 | Koehler Maria | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 6.51 | 114.1K | 17,520 | — | ↗ |
| 2023-06-09 | Hughes Owen | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 6.51 | 114.1K | 17,520 | — | ↗ |
| 2023-06-09 | FORMELA JEAN FRANCOIS | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 6.51 | 114.1K | 17,520 | — | ↗ |
| 2023-06-09 | Dukes Iain D. | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 6.51 | 114.1K | 17,520 | — | ↗ |
| 2023-06-09 | Bonita David P | Director | A-Award | A | Stock Option (Right to Buy) | 17,520 | 6.51 | 114.1K | 17,520 | — | ↗ |
| 2023-01-03 | Zhang Xiaoyan Michelle | Officer | A-Award | A | Stock Option (Right to Buy) | 105,000 | 0.00 | — | 105,000 | — | ↗ |
| 2023-01-03 | Santillana Sergio L. | Officer | A-Award | A | Stock Option (Right to Buy) | 105,000 | 0.00 | — | 105,000 | — | ↗ |
| 2023-01-03 | Marango Jotin | Officer | A-Award | A | Stock Option (Right to Buy) | 105,000 | 0.00 | — | 105,000 | — | ↗ |
| 2023-01-03 | Manfredi Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 220,000 | 0.00 | — | 220,000 | — | ↗ |
| 2023-01-03 | Ecsedy Jeffrey | Officer | A-Award | A | Stock Option (Right to Buy) | 105,000 | 0.00 | — | 105,000 | — | ↗ |
| 2022-12-15 | Hughes Owen | Director | A-Award | A | Stock Option (Right to Buy) | 35,040 | 0.00 | — | 35,040 | — | ↗ |
| 2022-12-14 | Hughes Owen | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-24 | ORBIMED ADVISORS LLC | Director | P-Purchase | D | Common Stock | 65,965 | 4.37 | 288.3K | 2,002,062 | — | ↗ |
| 2022-06-24 | Bonita David P | Director | P-Purchase | D | Common Stock | 96,035 | 5.37 | 515.7K | 2,098,097 | — | ↗ |
| 2022-06-23 | ORBIMED ADVISORS LLC | Director | P-Purchase | D | Common Stock | 23,419 | 3.71 | 86.9K | 1,936,097 | — | ↗ |
| 2022-06-22 | OrbiMed Genesis GP LLC | Director | P-Purchase | D | Common Stock | 66,806 | 3.55 | 237.2K | 1,912,678 | — | ↗ |
| 2022-06-22 | ORBIMED ADVISORS LLC | Director | P-Purchase | D | Common Stock | 66,806 | 3.55 | 237.2K | 1,912,678 | — | ↗ |
| 2022-06-22 | Bonita David P | Director | P-Purchase | D | Common Stock | 66,806 | 3.55 | 237.2K | 1,912,678 | — | ↗ |
| 2022-06-09 | Wooster Richard | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 4.85 | 65.1K | 13,419 | — | ↗ |
| 2022-06-09 | Stampacchia Otello | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 0.00 | — | 13,419 | — | ↗ |
| 2022-06-09 | Renaud Ronald C JR | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 0.00 | — | 13,419 | — | ↗ |
| 2022-06-09 | Koehler Maria | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 4.85 | 65.1K | 13,419 | — | ↗ |
| 2022-06-09 | FORMELA JEAN FRANCOIS | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 0.00 | — | 13,419 | — | ↗ |
| 2022-06-09 | Dukes Iain D. | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 4.85 | 65.1K | 13,419 | — | ↗ |
| 2022-06-09 | Bonita David P | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 0.00 | — | 13,419 | — | ↗ |
| 2022-04-25 | Marango Jotin | Officer | A-Award | A | Stock Option (Right to Buy) | 397,199 | 0.00 | — | 397,199 | — | ↗ |
| 2022-02-18 | Oliveira Francisco | Officer | — | D | Stock Option (Right to Buy) | 11,182 | 7.87 | 88.0K | 0 | — | ↗ |
| 2022-02-03 | Manfredi Mark | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 238,900 | 9.76 | 2.33M | 238,900 | — | ↗ |
| 2022-02-02 | Zhang Xiaoyan Michelle | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 11.45 | 458.0K | 40,000 | — | ↗ |
| 2022-02-02 | Tessier Maude | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 11.45 | 458.0K | 40,000 | — | ↗ |
| 2022-02-02 | Santillana Sergio L. | Officer | A-Award | A | Stock Option (Right to Buy) | 70,400 | 11.45 | 806.1K | 70,400 | — | ↗ |
| 2022-02-02 | Ecsedy Jeffrey | Officer | A-Award | A | Stock Option (Right to Buy) | 59,360 | 11.45 | 679.7K | 59,360 | — | ↗ |
| 2022-01-21 | Wooster Richard | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-18 | Tessier Maude | Officer | M-Exempt | A | Common Stock | 8,265 | 4.51 | 37.3K | 100,578 | — | ↗ |
| 2022-01-11 | Zhang Xiaoyan Michelle | Officer | S-Sale | D | Common Stock | 964 | 12.00 | 11.6K | 44,475 | — | ↗ |
| 2022-01-10 | Zhang Xiaoyan Michelle | Officer | M-Exempt | D | Stock Option (Right to Buy) | 36 | 2.15 | 77.26 | 25,437 | — | ↗ |
| 2021-12-21 | Stampacchia Otello | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 14.92 | 200.2K | 13,419 | — | ↗ |
| 2021-12-21 | Renaud Ronald C JR | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 14.92 | 200.2K | 13,419 | — | ↗ |
| 2021-12-21 | Koehler Maria | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 14.92 | 200.2K | 13,419 | — | ↗ |
| 2021-12-21 | FORMELA JEAN FRANCOIS | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 14.92 | 200.2K | 13,419 | — | ↗ |
| 2021-12-21 | Dukes Iain D. | Director | A-Award | A | Stock Option (Right to Buy) | 23,419 | 14.92 | 349.4K | 23,419 | — | ↗ |
| 2021-12-21 | Bonita David P | Director | A-Award | A | Stock Option (Right to Buy) | 13,419 | 14.92 | 200.2K | 13,419 | — | ↗ |
| 2021-12-14 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 5,959 | 14.00 | 83.4K | 1,241,935 | — | ↗ |
| 2021-12-14 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 5,959 | 14.00 | 83.4K | 1,241,935 | — | ↗ |
| 2021-12-13 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 8,330 | 14.64 | 122.0K | 1,247,894 | — | ↗ |
| 2021-12-13 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 8,330 | 14.64 | 122.0K | 1,247,894 | — | ↗ |
| 2021-12-10 | Zhang Xiaoyan Michelle | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,000 | 2.15 | 2.1K | 25,473 | — | ↗ |
| 2021-12-10 | FORMELA JEAN FRANCOIS | Director | S-Sale | D | Common Stock | 11,989 | 15.03 | 180.2K | 1,256,224 | — | ↗ |
| 2021-12-10 | Atlas Venture Fund XI, L.P. | 10% Owner | S-Sale | D | Common Stock | 11,989 | 15.03 | 180.2K | 1,256,224 | — | ↗ |
| 2021-11-22 | Zhang Xiaoyan Michelle | Officer | — | D | Stock Option (Right to Buy) | 19,427 | 4.15 | 80.6K | 0 | — | ↗ |
| 2021-04-15 | Koehler Maria | Director | A-Award | A | Stock Option (Right to Buy) | 26,838 | 18.45 | 495.2K | 26,838 | — | ↗ |
| 2021-03-30 | Stampacchia Otello | Director | A-Award | A | Common Stock | 450,000 | 16.00 | 7.20M | 2,249,123 | — | ↗ |
| 2021-03-30 | FORMELA JEAN FRANCOIS | Director | C-Conversion | A | Common Stock | 1,099,118 | 0.00 | — | 1,268,213 | — | ↗ |
| 2021-03-30 | Atlas Venture Fund XI, L.P. | 10% Owner | P-Purchase | A | Common Stock | 125,000 | 16.00 | 2.00M | 874,634 | — | ↗ |
| 2021-03-30 | Atlas Venture Fund X, L.P. | 10% Owner | C-Conversion | D | Series B Preferred Stock | 5,362,888 | 0.00 | — | 0 | — | ↗ |
| 2021-03-25 | Tessier Maude | Officer | — | D | Common Stock | 0 | 0.00 | — | 28,792 | — | ↗ |
| 2021-03-25 | Stampacchia Otello | Director | — | I | Series B Preferred Stock | 1,799,123 | 0.00 | — | 0 | — | ↗ |
| 2021-03-25 | Santillana Sergio L. | Officer | — | D | Stock Option (Right to Buy) | 157,711 | 4.51 | 711.3K | 0 | — | ↗ |
| 2021-03-25 | Renaud Ronald C JR | Director | — | D | Stock Option (Right to Buy) | 97,847 | 7.87 | 770.1K | 0 | — | ↗ |
| 2021-03-25 | ORBIMED ADVISORS LLC | Director | — | I | Series B Preferred Stock | 113,038 | 0.00 | — | 0 | — | ↗ |
| 2021-03-25 | Manfredi Mark | Director / Officer | — | D | Stock Option (Right to Buy) | 95,305 | 1.15 | 109.6K | 0 | — | ↗ |
| 2021-03-25 | FORMELA JEAN FRANCOIS | Director | — | I | Series A-1 Preferred Stock | 1,573,682 | 0.00 | — | 0 | — | ↗ |
| 2021-03-25 | Ecsedy Jeffrey | Officer | — | D | Stock Option (Right to Buy) | 191,980 | 7.87 | 1.51M | 0 | — | ↗ |
| 2021-03-25 | Dukes Iain D. | Director | — | D | Stock Option (Right to Buy) | 19,061 | 1.15 | 21.9K | 0 | — | ↗ |
| 2021-03-25 | Carlson Douglas R | Officer | — | D | Stock Option (Right to Buy) | 177,904 | 4.15 | 738.3K | 0 | — | ↗ |
| 2021-03-25 | Bonita David P | Director | — | I | Series A Preferred Stock | 2,585,967 | 0.00 | — | 0 | — | ↗ |
| 2021-03-25 | Atlas Venture Fund XI, L.P. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 169,095 | — | ↗ |
| 2020-12-21 | Stampacchia Otello | Director | A-Award | A | Series B Preferred Stock | 12,870,933 | 0.00 | — | 12,870,933 | — | ↗ |
| 2020-12-21 | FORMELA JEAN FRANCOIS | Director | A-Award | A | Series B Preferred Stock | 5,362,888 | 0.00 | — | 5,362,888 | — | ↗ |
| 2010-12-31 | Chiniara Ellen | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-10-30 | Chiniara Ellen | Officer | M-Exempt | A | Employee Stock Option (Right to Buy) | 5,000 | 38.01 | 190.1K | 5,000 | — | ↗ |
| 2009-06-30 | Chiniara Ellen | Officer | M-Exempt | A | Employee Stock Option (Right to Buy) | 8,331 | 35.58 | 296.4K | 8,331 | — | ↗ |
| 2008-12-31 | Chiniara Ellen | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-12-31 | Chiniara Ellen | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-10-31 | QUELCH JOHN | Director | A-Award | A | Employee Stock Option (Right to Buy) | 24,204 | 60.09 | 1.45M | 24,204 | — | ↗ |
| 2007-05-07 | Chiniara Ellen | Officer | — | D | Employee Stock Option (Right to Buy) | 25,000 | 37.74 | 943.5K | 0 | — | ↗ |
| 2006-02-14 | LINDOP CHRISTOPHER J | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2005-05-24 | QUELCH JOHN | Director | A-Award | A | Employee Stock Option (Right to Buy) | 25,000 | 28.03 | 700.8K | 25,000 | — | ↗ |
| 2003-12-31 | LINDOP CHRISTOPHER J | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 7,435 | 21.78 | 161.9K | 7,435 | — | ↗ |
| 2003-10-01 | LINDOP CHRISTOPHER J | Officer | — | D | Employee Stock Option (Right to Buy) | 75,000 | 24.20 | 1.82M | 0 | — | ↗ |
| 2003-09-22 | LINDOP CHRISTOPHER J | Officer | — | D | Employee Stock Option (right to buy) | 75,000 | 24.20 | 1.82M | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-48.5K
Shares Outstanding
11.28M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Kristin Yarema, Ph.D. Chief Executive Officer | 274.6K | 291.9K | 1.31M | 6.15M | 138.1K | 5.7K | 8.17M | 91.31% | ↗ |
| 2 | 2025 | Mark Manfredi, Ph.D. Former President and Chief Executive Officer | 338.7K | 890.0K | — | — | — | 1.48M | 2.71M | 0.00% | ↗ |
| 3 | 2025 | Jotin Marango, M.D., Ph.D. Former Chief Financial Officer | 392.6K | 905.0K | — | — | — | 271.6K | 1.57M | 0.00% | ↗ |
| 4 | 2025 | YuFang Lu, M.D., Ph.D. Former Chief Medical Officer | 452.0K | — | — | — | — | 195.8K | 647.9K | 0.00% | ↗ |
| 5 | 2024 | Jotin Marango, M.D., Ph.D. Former Chief Financial Officer | 456.1K | 165.0K | — | 701.2K | 188.0K | 813.00 | 1.51M | 46.40% | ↗ |
| 6 | 2024 | Mark Manfredi, Ph.D. Former President and Chief Executive Officer | 569.0K | — | — | 334.0K | 284.5K | 14.7K | 1.20M | 27.78% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kristin Yarema | Chief Executive Officer, Director & Interim Principal Financial Officer | 710.3K | — |
| Benjamin Porter-Brown | Chief Medical Officer | 588.4K | — |
| Bob Lally | Senior VP of Finance & Operations and Principal Accounting Officer | — | male |
| Kurinji Pandiyan | Chief Strategy & Operations Officer | — | — |
| Renuka Sivendran | Chief Technical Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IMA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
